Nektar Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $23,489 | $21,639 | $23,885 | $24,144 |
Gross Profit | 13,749 | 13,105 | 16,602 | 11,713 |
EBITDA | -35,026 | -32,845 | -29,008 | -28,628 |
EBIT | -36,485 | -34,452 | -30,660 | -30,323 |
Net Income | -52,363 | -36,802 | -42,079 | -45,837 |
Net Change In Cash | 23,489 | 21,639 | 23,885 | 24,144 |
Free Cash Flow | -37,888 | -48,045 | -47,284 | -42,154 |
Cash | 13,920 | 34,744 | 20,161 | 64,921 |
Basic Shares | 208,828 | 194,746 | 191,040 | 190,406 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $90,122 | $92,055 | $101,907 | $152,915 |
Gross Profit | 53,478 | 70,420 | 77,010 | 133,438 |
EBITDA | -129,610 | -220,539 | -453,798 | -347,458 |
EBIT | -137,425 | -232,739 | -466,798 | -359,958 |
Net Income | -276,056 | -368,198 | -523,837 | -444,440 |
Net Change In Cash | 90,122 | 92,055 | 101,907 | 152,915 |
Cost of Revenue | -173,645 | 102,572 | ||
Free Cash Flow | -193,471 | -309,683 | -427,649 | -320,545 |
Cash | 20,161 | 88,227 | 25,218 | 198,955 |
Basic Shares | 190,001 | 187,138 | 183,298 | 178,581 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.25 |
2024-03-31 | -$0.19 |
2023-12-31 | -$0.22 |
2023-09-30 | -$0.24 |
